Acasti Pharma jumps as brain bleed drug shows promise

Grace Therapeutics

02/12/2021 12:53

** Drugmaker's shares  ACST.O  rise 7% to $1.36 premarket,
seen pulling away from all-time lows hit in the previous session
    ** Co said its drug candidate, GTX-104, met main goals in a
pharmacokinetic bridging study for first 20 of 50 normal healthy
subjects  urn:newsml:reuters.com:*:nFWN2SN0MW
    ** Shares set for best session in seven weeks
    ** GTX-104 is being developed as an IV infusion for patients
experiencing Subarachnoid Hemorrhage, or bleeding over the
surface of the brain triggered by a ruptured aneurysm 
    ** If the final study results are consistent with interim
results, co could initiate late-stage study in second half of
2022 - Acasti's CEO
    ** ACST down ~50% YTD as of last close

 (Reporting by Susan Mathew)
 ((susan.mathew@thomsonreuters.com))